Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More
you are here: HomeNewsTrendsHealth

India's COVID-19 surge and the new variant: what we know

A key question is whether a new variant with potentially worrying mutations -- B.1.617 -- is behind what is currently the world's fastest-growing outbreak, which added more than 300,000 fresh infections on Thursday.

April 22, 2021 / 04:43 PM IST

India is battling a record-breaking rise in COVID-19 infections that has overwhelmed hospitals and led to severe bed and oxygen shortages.

A key question is whether a new variant with potentially worrying mutations -- B.1.617 -- is behind what is currently the world's fastest-growing outbreak, which added more than 300,000 fresh infections Thursday.

The B.1.617 variant has already appeared elsewhere, including in the United States, Australia, Israel and Singapore. Concern about it has led some countries, including the UK, to slap travel restrictions on India.

Here's what we know.

When did it emerge?

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Viruses change all the time and the one that causes COVID-19 has already undergone several thousand mutations -- some more concerning than others.

India first reported the B.1.617 genome to the global database (GISAID) in October.

India's health ministry flagged the variant in late March, saying it appeared in 15-20 percent of samples analysed from the worst-hit state Maharashtra.

More recently, the figure was 60 percent.

The variant has also been detected in 18 other countries as of this month, according to GISAID.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

Should we worry?

B.1.617 has been categorised by the World Health Organisation as a "variant of interest".

Other variants detected in Brazil, South Africa and the UK have been categorised as "of concern", because they are more transmissible, virulent or might reduce antibody efficacy.

B.1.617 has several mutations, including two notable ones (E484Q and L452R), leading to it sometimes being called the "double mutant".

The first notable mutation is similar to another (E484K or sometimes nicknamed "Eek") observed in the South African, Brazilian, and more recently, the UK variants.

The "Eek" has been dubbed an "escape mutation" as it helps the virus get past the body's immune system.

The other notable mutation was found by a Californian study to be an efficient spreader.

Scientists say more evidence is needed to determine if these mutations make the B.1.617 variant more dangerous.

Is it behind India's spike?

Rakesh Mishra, director of the Hyderabad-based Centre for Cellular and Molecular Biology, is one of the scientists currently analysing the B.1.617 variant.

So far, he says it has been "better in terms of spreading compared to other variants".

"Slowly it will become the more common one and it will replace the other variants," he told AFP.

It is not yet known, however, if India's current wave is linked to this variant, or if it is being driven by human behaviour or something else.

Health experts have raised "super spreader" concerns over recent huge religious festivals and political rallies with mostly maskless crowds.

Still, several countries are taking no chances with B.1.617. When it banned travel from India this week, the UK specifically cited fears of the new variant.

The United States on Wednesday also advised against travel to India, noting that "even fully vaccinated travellers may be at risk for getting and spreading COVID-19 variants".

Are vaccines effective against it?

One of the mutations is related to "Eek", which is suspected of reducing antibody protection from a previous infection or vaccination, said University of Utah evolutionary virology researcher, Stephen Goldstein.

Mishra says scientists were testing vaccine efficacy against the variant.

Even so, experts say vaccines still offer some protection, particularly from severe cases.

Also Read: Vaccination to 18-45 yr old people will not be free at central govt-run hospitals, says RS Sharma

What's next?

Since more variants emerge when there are more infected hosts, Mishra said India needs to get its outbreak under control.

Another variant, the B.1.618, recently raised red flags when it became the third-most detected in India.

Goldstein pointed to the UK's success at turning around a recent outbreak despite the presence of a more transmissible variant.

"It can be quite onerous, but it can be done," he told AFP.

"I think the vaccination campaign certainly helped... but it's the lockdown that enabled them to slow the rise of cases and start to turn the corner."

Follow our full coverage of the coronavirus pandemic here.
AFP

stay updated

Get Daily News on your Browser
Sections